Provided by Tiger Trade Technology Pte. Ltd.

CLIMB BIO INC

5.44
+0.790016.99%
Post-market: 5.39-0.0500-0.92%19:46 EST
Volume:893.70K
Turnover:4.67M
Market Cap:259.73M
PE:-7.25
High:5.45
Open:4.72
Low:4.70
Close:4.65
52wk High:5.60
52wk Low:1.05
Shares:47.74M
Float Shares:30.75M
Volume Ratio:2.02
T/O Rate:2.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7507
EPS(LYR):-1.5343
ROE:-25.65%
ROA:-17.35%
PB:1.47
PE(LYR):-3.55

Loading ...

Company Profile

Company Name:
CLIMB BIO INC
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
18
Office Location:
20 William Street,Suite 145,Wellesley Hills,Massachusetts,United States
Zip Code:
02481
Fax:
- -
Introduction:
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Directors

Name
Position
Aoife Brennan
Director, President and Chief Executive Officer
Alexander Cumbo
Director
Andrew Levin
Director
Douglas Williams
Director
Judith Dunn
Director
Kimberlee Drapkin
Director
Stephen Thomas
Director

Shareholders

Name
Position
Aoife Brennan
Director, President and Chief Executive Officer
Cindy Driscoll
Senior Vice President, Finance and Principal Accounting Officer
Susan Altschuller
Chief Financial Officer and Treasurer